NEUROCRINE BIOSCIENCES INC — Form 8-K/A
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 72/100
What the filing says
On May 18, 2026, Neurocrine Biosciences completed its acquisition of Soleno Therapeutics for $53.00 per share in cash. The transaction added VYKAT XR (diazoxide choline), a first-in-class therapy for hyperphagia in Prader-Willi syndrome. Neurocrine funded the deal with a $1.0B revolving credit facility (drew $600M on closing, fully repaid by June 30), and pro forma 2025 combined net income would have been $324.5M vs. standalone $478.6M for Neurocrine, reflecting $235.6M in acquisition-related charges including $139.9M intangible asset amortization and $168.2M inventory step-up.
Why this rating
Material M&A (likely $2.8-3.0B transaction ~30% of $9.5B market cap) adds commercial-stage product and rare-disease capability, but substantial non-cash acquisition charges reduce near-term reported earnings; transformational strategic move with unclear near-term margin impact.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.